Scotia Capital’s Parexel International Corp PRXL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q1
Sell
-3,950
Closed -$260K 879
2016
Q4
$260K Sell
3,950
-615
-13% -$38.6K ﹤0.01% 688
2016
Q3
$315K Buy
4,565
+1,135
+33% +$76.6K 0.01% 651
2016
Q2
$216K Sell
3,430
-110
-3% -$6.81K ﹤0.01% 644
2016
Q1
$222K Sell
3,540
-3,925
-53% -$242K ﹤0.01% 611
2015
Q4
$511K Hold
7,465
0.01% 562
2015
Q3
$462K Buy
7,465
+2,275
+44% +$153K 0.01% 565
2015
Q2
$331K Buy
5,190
+615
+13% +$41.4K 0.01% 608
2015
Q1
$316K Buy
+4,575
New +$292K 0.01% 511
2014
Q4
Sell
-3,220
Closed -$203K 636
2014
Q3
$203K Buy
+3,220
New +$183K ﹤0.01% 549

Other funds holding PRXL

Scotia Capital's PRXL Position: Q1 2017 in Review

Scotia Capital sold out of Parexel International Corp (PRXL) in Q1 2017, closing a stake of 3,950 shares — an estimated $260K sold.

Scotia Capital first reported a position in PRXL in Q3 2014 and held it in 9 quarters. The position peaked at $511K in Q4 2015. 308 funds tracked by Wall St. Rank hold PRXL as of Q1 2017.

  • Scotia Capital reported no remaining Parexel International Corp position as of Q1 2017 after selling out during the quarter.
  • Scotia Capital sold 3,950 Parexel International Corp shares in Q1 2017, an estimated $260K.
  • Scotia Capital first reported a position in Parexel International Corp in Q3 2014 and held it in 9 quarters.
  • Scotia Capital's Parexel International Corp position peaked at $511K in Q4 2015.
  • 308 funds tracked by Wall St. Rank held Parexel International Corp as of Q1 2017.

Based on Scotia Capital's 13F filing for Q1 2017, filed 15 May 2017.